Blood Test Detects All Known Inherited Heart Conditions Genes
By LabMedica International staff writers Posted on 28 Feb 2016 |
A rapid, simple blood test has been developed that accurately can detect all known genes associated with inherited heart conditions which are characterized by marked genetic and allelic heterogeneity and require extensive sequencing for genetic characterization.
Inherited heart conditions are caused by gene mutations that have been passed down from relatives. If a mother possesses one of these faulty genes, there is a 50% chance that they will pass the mutation on to their child. These heart conditions include aortic valve disease, structural heart disease, long and short QT syndrome, Noonan syndrome, familial atrial fibrillation and most cardiomyopathies.
Scientists at the Imperial College London (UK) working with their colleagues analyzed the blood samples of 348 participants from the National Heart Center (Singapore). Genomic DNA was extracted from blood using Prepito DNA Blood 600 kit (Perkin Elmer, Waltham, MA, USA) for targeted sequencing; EZ1 DSP DNA blood 48 kit (Qiagen, Venlo, Netherlands) for whole exome sequencing, (WES) or the Qiagen QIAsymphony DNA kit for whole genome sequencing (WGS).
Quality and quantity of extracted DNA were assessed by an ultraviolet-visible spectrophotometer. For targeted sequencing pooled libraries were prepared using the inherited cardiac conditions (ICC) panel and were sequenced on the MiSeq (108 samples) or NextSeq 500 (144samples) benchtop sequencers (Illumina; San Diego, CA, USA) using paired-end, 150 bp reads. Pathogenic or likely pathogenic variants of 26 samples were identified using the ICC panel in a study cohort of 35 samples was subjected to Sanger sequencing.
The new test used next-generation sequencing to simultaneously identify 174 genes known to increase the risk of 17 inherited heart conditions. The team found that the test was able to quickly identify all gene mutations in the blood samples that were associated with the 17 inherited heart conditions with up to 100% accuracy. The assay has better performance, shorter turnaround times, lesser informatics requirements and lower sequencing costs as compared to the WES, deep WES, and WGS. The assay is called the TruSight Cardio Sequencing Kit.
James S. Ware, MD, PhD, a cardiologist and coauthor of the study said, “Without a genetic test, we often have to keep the whole family under regular surveillance for many years, because some of these conditions may not develop until later in life. This is hugely costly for both the families and the health system. By contrast, when a genetic test reveals the precise genetic abnormality causing the condition in one member of the family, it becomes simple to test other family members. Those who do not carry the faulty gene copy can be reassured and spared countless hospital visits. This new comprehensive test is increasing the number of families who benefit from genetic testing.” The study was published on February 17, 2016, in the Journal of Cardiovascular Translational Research.
Related Links:
Imperial College London
Singapore National Heart Center
Illumina
Inherited heart conditions are caused by gene mutations that have been passed down from relatives. If a mother possesses one of these faulty genes, there is a 50% chance that they will pass the mutation on to their child. These heart conditions include aortic valve disease, structural heart disease, long and short QT syndrome, Noonan syndrome, familial atrial fibrillation and most cardiomyopathies.
Scientists at the Imperial College London (UK) working with their colleagues analyzed the blood samples of 348 participants from the National Heart Center (Singapore). Genomic DNA was extracted from blood using Prepito DNA Blood 600 kit (Perkin Elmer, Waltham, MA, USA) for targeted sequencing; EZ1 DSP DNA blood 48 kit (Qiagen, Venlo, Netherlands) for whole exome sequencing, (WES) or the Qiagen QIAsymphony DNA kit for whole genome sequencing (WGS).
Quality and quantity of extracted DNA were assessed by an ultraviolet-visible spectrophotometer. For targeted sequencing pooled libraries were prepared using the inherited cardiac conditions (ICC) panel and were sequenced on the MiSeq (108 samples) or NextSeq 500 (144samples) benchtop sequencers (Illumina; San Diego, CA, USA) using paired-end, 150 bp reads. Pathogenic or likely pathogenic variants of 26 samples were identified using the ICC panel in a study cohort of 35 samples was subjected to Sanger sequencing.
The new test used next-generation sequencing to simultaneously identify 174 genes known to increase the risk of 17 inherited heart conditions. The team found that the test was able to quickly identify all gene mutations in the blood samples that were associated with the 17 inherited heart conditions with up to 100% accuracy. The assay has better performance, shorter turnaround times, lesser informatics requirements and lower sequencing costs as compared to the WES, deep WES, and WGS. The assay is called the TruSight Cardio Sequencing Kit.
James S. Ware, MD, PhD, a cardiologist and coauthor of the study said, “Without a genetic test, we often have to keep the whole family under regular surveillance for many years, because some of these conditions may not develop until later in life. This is hugely costly for both the families and the health system. By contrast, when a genetic test reveals the precise genetic abnormality causing the condition in one member of the family, it becomes simple to test other family members. Those who do not carry the faulty gene copy can be reassured and spared countless hospital visits. This new comprehensive test is increasing the number of families who benefit from genetic testing.” The study was published on February 17, 2016, in the Journal of Cardiovascular Translational Research.
Related Links:
Imperial College London
Singapore National Heart Center
Illumina
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans